<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="monograph-family" /><meta name="keywords" content="Anticoagulants: oral; Coumarins; Warfarin; Acenocoumarol; Phenindione; Thrombosis: deep-vein; Deep-vein thrombosis; Thromboembolism; Atrial fibrillation; Atrial fibrillation; Arterial occlusion; Anticoagulants: oral: reversal; Human prothrombin complex see Dried prothrombin complex; Dried prothrombin complex; Prothrombin complex, dried; Pregnancy: anticoagulants; Anticoagulant treatment booklets; Treatment cards, anticoagulant" /><meta name="IX" content="Anticoagulants: oral; Coumarins; Warfarin; Acenocoumarol; Phenindione; Thrombosis: deep-vein; Deep-vein thrombosis; Thromboembolism; Atrial fibrillation; Atrial fibrillation; Arterial occlusion; Anticoagulants: oral: reversal; Dried prothrombin complex; Prothrombin complex, dried; Pregnancy: anticoagulants; Anticoagulant treatment booklets; Treatment cards, anticoagulant" /><meta name="IXN" content="Human prothrombin complex see Dried prothrombin complex" /><title>Coumarins and phenindione: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="201052.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="201052.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=201052.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="1002.htm">2 Cardiovascular system</a> &gt; <a href="2760.htm">2.8 Anticoagulants and protamine</a> &gt; <a href="2791.htm">2.8.2 Oral anticoagulants</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="2791.htm" title="Previous: 2.8.2 Oral anticoagulants">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="2792.htm" title="Next: WARFARIN SODIUM">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_201052">Coumarins and phenindione</h1><?highlighter on?><div id="pC" class="jN"><div class="cAJ"><span class="cAD">Additional information</span> interactions (<a href="41001i222.htm" title="Go to appendix 1">Warfarin</a>).</div><div><p>The oral anticoagulants <b>warfarin</b>, <b>acenocoumarol</b> and <b>phenindione</b>, antagonise the effects of vitamin K, and take at least 48 to 72
hours for the anticoagulant effect to develop fully; warfarin is the
drug of choice. If an immediate effect is required, unfractionated
or low molecular weight <span>heparin</span> must be given concomitantly.</p><div class="cAZ"><h2>Uses</h2> <p class="cAX">Indications for these oral anticoagulants
include <i>deep-vein thrombosis</i>, <i>pulmonary embolism</i>,  <i>atrial fibrillation</i> in those who are at risk of embolisation
(see also <a title=" Management of arrhythmias" href="2409.htm#_2409">section 2.3.1</a>), and <i>mechanical prosthetic
heart valves</i> (to prevent emboli developing on the valves).</p><p><span id="_2791.2">These oral
anticoagulants should not be used in cerebral artery thrombosis or
peripheral artery occlusion as first-line therapy; <span>aspirin</span> is more appropriate
for reduction of risk in transient ischaemic attacks (see <a title="BNF:topic: Transient ischaemic attack" href="213884.htm#_213884">section 2.9</a>). Unfractionated or a low
molecular weight heparin (<a title="sub-section: Parenteral anticoagulants" href="2761.htm#_2761">section 2.8.1</a>) is usually preferred for the
prophylaxis of venous thromboembolism in patients undergoing surgery;
alternatively, warfarin can be continued in selected patients currently
taking long-term warfarin and who are at high risk of thromboembolism
(seek expert advice)</span>.</p></div><div class="cAZ"><h2>Dose</h2> <p class="cAX">The base-line prothrombin time
should be determined but the initial dose should not be delayed whilst
awaiting the result. </p><p>For patients who require rapid anticoagulation the usual adult
induction dose of warfarin is 5–10 mg on the first day (elderly patients
should receive a lower induction dose); subsequent doses depend upon
the prothrombin time, reported as INR (international normalised ratio).
For patients who do not require rapid anticoagulation, a lower loading
dose can be used over 3–4 weeks. The daily maintenance dose of warfarin
is usually 3–9 mg (taken at the <b>same time</b> each day).</p></div><div class="cAZ"><h2>Target INR</h2> <p class="cAX">The following indications and target
INRs<sup class="footnote"><a title="Go to footnote" href="201052.htm#footnote112937">(1)</a></sup> for warfarin
take into account recommendations of the British Society for Haematology<sup class="footnote"><a title="Go to footnote" href="201052.htm#footnote112938">(2)</a></sup>:</p><p>INR 2.5 for:</p><ul class="cBF"><li><p class="cQ">treatment of deep-vein thrombosis or pulmonary embolism
(including those associated with antiphospholipid syndrome or for
recurrence in patients no longer receiving warfarin)</p></li><li><p class="cQ">atrial fibrillation (see also <a title="BNF:sub-section: Management of arrhythmias" href="2409.htm#_2409">section 2.3.1</a>)</p></li><li><p class="cQ">cardioversion—target INR should be achieved at least 3
weeks before cardioversion and anticoagulation should continue for
at least 4 weeks after the procedure (higher target values, such as
an INR of 3, can be used for up to 4 weeks before the procedure to
avoid cancellations due to low INR)</p></li><li><p class="cQ">dilated cardiomyopathy</p></li><li><p class="cQ">mitral stenosis or regurgitation in patients with either
atrial fibrillation, a history of systemic embolism, a left atrial
thrombus, or an enlarged left atrium</p></li><li><p class="cQ">bioprosthetic heart valves in the mitral position (treat
for 3 months), or in patients with a history of systemic embolism
(treat for at least 3 months), or with a left atrial thrombus at surgery
(treat until clot resolves), or with other risk factors (e.g. atrial
fibrillation or a low ventricular ejection fraction)</p></li><li><p class="cQ">acute arterial embolism requiring embolectomy (consider
long-term treatment)</p></li><li><p class="cQ">myocardial infarction (see also <a title="BNF:target-block: Long-term management" href="204270.htm#_60552.1">section 2.10.1</a>);</p></li></ul><p>INR 3.5 for:</p><ul class="cBF"><li><p class="cQ">recurrent deep-vein thrombosis or pulmonary embolism in
patients currently receiving anticoagulation and with an INR above
2;</p></li></ul><p>Mechanical prosthetic heart valves:</p><ul class="cBF"><li><p class="cQ">the recommended target INR depends on the type and location
of the valve, and patient-related risk factors</p></li><li><p class="cQ">consider increasing the INR target or adding an antiplatelet
drug, if an embolic event occurs whilst anticoagulated at the target
INR.</p></li></ul></div><div class="cAZ"><h2>Duration</h2> <p class="cAX">The risks of thromboembolism recurrence
and anticoagulant-related bleeding should be considered when deciding
the duration of anticoagulation.</p><p>The following durations of warfarin for the treatment of deep-vein thrombosis and pulmonary embolism reflect the recommendations
of the British Society for Haematology<sup class="footnote"><a title="Go to footnote" href="201052.htm#footnote112938">(2)</a></sup>:</p><ul class="cBF"><li><p class="cQ">6 weeks for isolated calf-vein deep-vein thrombosis</p></li><li><p class="cQ">3 months for venous thromboembolism provoked by surgery
or other transient risk factor (e.g. combined oral contraceptive use,
pregnancy, plaster cast)</p></li><li><p class="cQ"><i>at least</i> 3 months for unprovoked proximal
deep-vein thrombosis or pulmonary embolism; long-term anticoagulation
may be required.</p></li></ul></div><div class="cAZ"><h2>Monitoring</h2> <p class="cAX"><span id="_2791.3">It is essential that the INR
be determined daily or on alternate days in early days of treatment, <i>then</i> at longer intervals (depending on response<sup class="footnote"><a title="Go to footnote" href="201052.htm#footnote112939">(3)</a></sup>) <i>then</i> up to every 12 weeks</span>.</p></div><div id="_200798"><div class="cAZ"><h2>Haemorrhage</h2> <p class="cAX"> The main adverse effect of all oral anticoagulants
is haemorrhage. Checking the INR and omitting doses when appropriate
is essential; if the anticoagulant is stopped but not reversed, the
INR should be measured 2–3 days later to ensure that it is falling.
The cause of an elevated INR should be investigated. The following
recommendations (which take into account the recommendations of the
British Society for Haematology<sup class="footnote"><a title="Go to footnote" href="201052.htm#footnote112938">(2)</a></sup>) are based on
the result of the INR and whether there is major or minor bleeding;
the recommendations apply to patients taking warfarin:</p><ul class="cBF"><li><p class="cQ">Major bleeding—stop warfarin; give <span>phytomenadione</span> (vitamin K<sub>1</sub>) 5 mg by slow intravenous injection; give
dried prothrombin complex (factors II, VII, IX, and X—<a title="monograph: DRIED PROTHROMBIN COMPLEX" href="200797.htm#_200797">section 2.11</a>) 25–50 units/kg (if dried prothrombin
complex unavailable, fresh frozen plasma 15 mL/kg can be given but
is less effective); recombinant factor VIIa is not recommended for
emergency anticoagulation reversal</p></li><li><p class="cQ">INR &gt; 8.0, minor bleeding—stop warfarin; give phytomenadione
(vitamin K<sub>1</sub>) 1–3 mg by slow intravenous injection; repeat
dose of phytomenadione if INR still too high after 24 hours; restart
warfarin when INR &lt;5.0</p></li><li><p class="cQ">INR &gt; 8.0, no bleeding—stop warfarin; give phytomenadione
(vitamin K<sub>1</sub>) 1–5 mg by mouth using the intravenous preparation
orally [unlicensed use]; repeat dose of phytomenadione if INR still
too high after 24 hours; restart warfarin when INR &lt;5.0</p></li><li><p class="cQ">INR 5.0–8.0, minor bleeding—stop warfarin; give phytomenadione
(vitamin K<sub>1</sub>) 1–3 mg by slow intravenous injection; restart
warfarin when INR &lt;5.0</p></li><li><p class="cQ">INR 5.0–8.0, no bleeding—withhold 1 or 2 doses of warfarin
and reduce subsequent maintenance dose</p></li><li><p class="cQ">Unexpected bleeding at therapeutic levels—always investigate
possibility of underlying cause e.g. unsuspected renal or gastro-intestinal
tract pathology</p></li></ul></div></div><div class="cAZ"><h2>Peri-operative anticoagulation</h2> <p class="cAX">Warfarin should
usually be stopped 5 days before elective surgery; phytomenadione
(vitamin K<sub>1</sub>) 1–5 mg by mouth (using the intravenous preparation
orally [unlicensed use]) should be given the day before surgery if
the INR is ≥1.5. If haemostasis is adequate, warfarin can be resumed
at the normal maintenance dose on the evening of surgery or the next
day.</p><p>Patients stopping warfarin prior to surgery who are considered
to be at high risk of thromboembolism (e.g. those with a venous thromboembolic
event within the last 3 months, atrial fibrillation with previous
stroke or transient ischaemic attack, or mitral mechanical heart valve)
may require interim therapy (‘bridging’) with a low molecular weight
heparin (using treatment dose). The low molecular weight heparin should
be stopped at least 24 hours before surgery; if the surgery carries
a high risk of bleeding, the low molecular weight heparin should not
be restarted until at least 48 hours after surgery.</p><p>Patients on warfarin who require emergency surgery that can
be delayed for 6–12 hours can be given intravenous phytomenadione
(vitamin K<sub>1</sub>) 5 mg to reverse the anticoagulant effect.
If surgery cannot be delayed, dried prothrombin complex (e.g. 25 units/kg)
can be given in addition to intravenous phytomenadione (vitamin K<sub>1</sub>) and the INR checked before surgery.</p></div><div id="_219198"><div class="cAZ"><h2>Combined anticoagulant and antiplatelet therapy</h2> <p class="cAX">Exisitng antiplatelet therapy following an acute coronary syndrome
or percutaneous coronary intervention should be continued for the
necessary duration according to the indication being treated (see <a title="BNF:section: Antiplatelet drugs" href="2802.htm#_2802">section 2.9</a>). The addition of warfarin, when
indicated (e.g. for venous thromboembolism or atrial fibrillation)
should be considered following an assessment of the patient’s risk
of bleeding and discussion with a cardiologist. The duration of treatment
with dual therapy (e.g. aspirin and warfarin) or triple therapy (e.g.
aspirin with clopidogrel and warfarin) should be kept to a minimum
where possible. The risk of bleeding with aspirin and warfarin dual
therapy is lower than with clopidogrel and warfarin. Depending on
the indications being treated and the patient’s risk of thromboembolism,
it may be possible to withhold antiplatelet therapy until warfarin
therapy is complete, or <i>vice versa</i> (on specialist
advice) in order to reduce the length of time on dual or triple therapy.
 </p></div></div><div id="_203972"><div class="cAZ"><h2>Hepatic impairment</h2> <p class="cAX">Warfarin, acenocoumarol, and
phenindione should be avoided in severe impairment, especially if
prothrombin time is already prolonged.</p></div></div><div id="_203973"><div class="cAZ"><h2>Renal impairment</h2> <p class="cAX">Warfarin, acenocoumarol, and
phenindione should be used with caution in mild to moderate impairment
and avoided in severe impairment.</p></div></div><div class="cAZ" id="_2791.1"><h2>Pregnancy</h2> <p class="cAX"> Warfarin, acenocoumarol, and
phenindione are teratogenic and should not be given in the first trimester
of pregnancy. Women of child-bearing age should be warned of this
danger since stopping these drugs before the sixth week of gestation
may largely avoid the risk of fetal abnormality. These oral anticoagulants cross the placenta
with risk of congenital malformations, and placental, fetal, or neonatal
haemorrhage, especially during the last few weeks of pregnancy and
at delivery. Therefore, if at all possible, they should be avoided
in pregnancy, especially in the first and third trimesters. Difficult
decisions may have to be made, particularly in women with prosthetic
heart valves, atrial fibrillation, or with a history of recurrent
venous thrombosis or pulmonary embolism.</p></div><div id="_203974"><div class="cAZ"><h2>Breast-feeding</h2> <p class="cAX">With warfarin, acenocoumarol, and
phenindione there is a risk of haemorrhage which is increased by vitamin-K
deficiency. Warfarin is not present in milk in significant amounts,
and appears safe, but phenindione should be avoided; the manufacturer
of acenocoumarol recommends prophylactic vitamin K for the infant
(consult product literature).</p></div></div><div class="cAZ"><h2>Treatment booklets</h2><p>Anticoagulant treatment booklets should
be issued to patients, and are available for purchase from:</p><address>3M Security Print and Systems Limited<br />Gorse Street, Chadderton<br />Oldham<br />OL9 9QH<br /></address><div class="cBA"><div>
      Tel:
      0845 610 1112</div></div><p>GP practices can obtain supplies through their Primary Care
Trust (PCT) or Agency stores. NHS Hospitals can order supplies from <a href="https://www.nhsforms.co.uk" title="external link">www.nhsforms.co.uk</a> or by emailing nhsforms@mmm.com.</p><p>These booklets include advice for patients on anticoagulant
treatment, an alert card to be carried by the patient at all times,
and a section for recording of INR results and dosage information.
Electronic copies and further advice are also available at <a href="http://www.npsa.nhs.uk/nrls/alerts-and-directives/alerts/anticoagulant" title="external link">www.npsa.nhs.uk/nrls/alerts-and-directives/alerts/anticoagulant</a>.</p></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_2792"><a href="2792.htm" title="WARFARIN SODIUM">WARFARIN SODIUM</a></li><li id="_2795"><a href="2795.htm" title="ACENOCOUMAROL">ACENOCOUMAROL</a></li><li id="_2797"><a href="2797.htm" title="PHENINDIONE">PHENINDIONE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="2791.htm">Previous: 2.8.2 Oral anticoagulants</a> | <a class="top" href="201052.htm#">Top</a> | <a accesskey="]" href="2792.htm">Next: WARFARIN SODIUM</a> ►</div><div class="cF"><div class="footnote" id="footnote112937"><sup>(1)</sup>An INR which is within 0.5 units of the target value is generally
satisfactory; larger deviations require dosage adjustment. Target
values (rather than ranges) are now recommended. </div><div class="footnote" id="footnote112938"><sup>(2)</sup>Guidelines on Oral Anticoagulation with Warfarin—fourth edition. <i>Br J Haematol</i> 2011; <b>154</b>: 311–324</div><div class="footnote" id="footnote112939"><sup>(3)</sup><span id="_112939.1">Change in patient’s clinical condition, particularly
associated with liver disease, intercurrent illness, or drug administration,
necessitates more frequent testing. See also <b>interactions</b>, Appendix 1 (coumarins). Major
changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect warfarin control.</span></div></div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>